Skip to content
Summer 2026 · 26% off every plan with SUMMER26 See pricing
Optionomics
BHVN · 10-Q filed August 10, 2026

BHVN earnings analysis

What we found in BHVN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.

Our reading of the filing · Free to read, no account needed

The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, segment disclosures, or quantitative MD&A outlook, so revenue, margins, EPS, cash flow, and working-capital trends cannot be assessed. Risk factors were unchanged materially from the prior 10-K, while management reported effective disclosure controls as of June 30, 2026. Market-risk exposure appears limited, with a 1.00% interest-rate move estimated to affect investment fair value by approximately $0.2 million.

What stood out

The parts that mattered.

Pulled out of the filing itself, with the figures the company reported.

Foreign-currency exposure immaterial
Management reported that monetary exposures on the condensed consolidated balance sheet were immaterial as of June 30, 2026.
Limited interest-rate sensitivity
A 1.00% increase or decrease in interest rates would change the fair value of the investment portfolio by approximately $(0.2) million or $0.2 million, respectively.
No recorded investment credit losses
The company stated it had not experienced any credit losses or recorded any allowance for credit losses related to cash, cash equivalents, and short-term debt securities.
Disclosure controls effective
The CEO and CFO concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
No material control changes
There was no change in internal control over financial reporting during the 3 months ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, those controls.
What to watch

And the other side of it.

The offsets in the same document — the things a summary that only listed the good news would have left out.

Unhedged foreign-currency exposure
The company does not hedge foreign-currency exposure, and its operations include activities in countries outside the U.S.; monetary exposures were described as immaterial as of June 30, 2026.
Investment portfolio rate risk
The company does not hedge interest-rate exposure; a 1.00% rate move would change the investment portfolio's fair value by approximately $0.2 million in either direction.
No material risk-factor update
Risk factors had not changed materially from the December 31, 2025 Form 10-K filed March 2, 2026; therefore, no material new or updated risk-factor changes were identified.
Guidance

What they said about what is next.

The provided 10-Q text contains no quantitative revenue or EPS outlook; numeric guidance is not provided.

How we read the filing overall

The filing reads about the same as the one before it.

One reading of one document. It is not advice, and it is not a forecast.
Earlier filings

What came before.

10-Q · May 4, 2026
Biohaven Ltd. reported its Q1 2026 financial results with a net loss of $130.5 million, a significant improvement from a net loss of $221.7 million in Q1 2025, driven by a reduction in operating expenses primarily due…
10-K · March 2, 2026
Biohaven’s 2025 10‑K describes a strategic refocus (initiated Q4 2025) to prioritize three late‑stage platforms (Kv7 ion channel modulators, MoDE/TRAP extracellular degraders, and a myostatin‑activin program).…
10-Q · May 12, 2025
The 10-Q contains extensive clinical and pipeline updates but does not include period income statement, balance sheet or cash-flow line items in the text provided. Material corporate financing occurred after…
10-Q · August 9, 2024
Biohaven's 10-Q emphasizes an active clinical pipeline with multiple near-term catalysts (several topline readouts and trial initiations expected in H2 2024–H1 2025) and a series of material share-based transactions…

This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.

Read the next one first.

We read every filing BHVN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.

Cancel anytime · Month to month · Switch tiers whenever